NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Xgene Pharmaceutical Inc.

Xgene Pharmaceutical Inc.

Private
TaipeiHealthcare & Life Scienceshttps://xgenepharm.com/

Last Round

Series C

Nov 4, 2021

Total Funding Raised

$60M

Company Overview

Xgene Pharmaceutical Inc. is a biotechnology company that develops innovative, multimodal conjugated small molecule drugs to treat neurological disorders and chronic pain.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug developmentnon-opioid analgesicpain managementclinical-stage biotechneurological disorderslinker technologysmall-molecule drugsmultimodal therapylicensing agreementprodrugTRPM8 inhibitortransdermal analgesicpain reliefpharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Xgene Pharmaceutical Inc. Comparables

Compare Xgene Pharmaceutical Inc. with similar companies based on industry and business-model similarity.

Xgene Pharmaceutical Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Latigo Biotherapeutics
87%
Kallyope
78%
PharmNovo AB
77%

Xgene Pharmaceutical Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CNov 4, 2021
Series B ExtensionMay 4, 2019
Series BOct 1, 2018

Xgene Pharmaceutical Inc. Investors

Notable investors and investment history

Xgene Pharmaceutical Inc. investors
InvestorRounds
Taiwania CapitalSeries B Extension
CITIC SecuritiesSeries C
TF CapitalSeries B, Series A
Ping An VenturesSeries C, Series B
Hengxu CapitalSeries C
5Y CapitalSeries B, Series A
Yijing CapitalSeries C

Xgene Pharmaceutical Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Xgene Pharmaceutical Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Xgene Pharmaceutical Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersTaipei
Employee Range3
Year Founded2015
Last FundingNov 4, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.